Comparison of safety and efficacy of desidustat with erythropoietin in newly diagnosed patient of anemia in chronic kidney disease: a prospective, open label, randomized controlled trial
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20251833Keywords:
Anemia, Chronic kidney disease, Desidustat, ErythropoietinAbstract
Background: Anemia is a frequent complication of chronic kidney disease (CKD), affecting quality of life and increasing cardiovascular risks. Erythropoiesis-stimulating agents (ESAs) like erythropoietin are standard treatments but raise concerns about safety and long-term outcomes. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), such as desidustat, have emerged as potential alternatives. This study compared the safety and efficacy of desidustat with erythropoietin in adults with CKD-associated anemia.
Methods: A randomized controlled trial was conducted in the Departments of Nephrology and Pharmacology at Dr. R.P.G.M.C. Kangra at Tanda. Adult CKD patients (>18 years) with anemia, whether on dialysis or not, were enrolled. Participants received either oral desidustat (50 mg thrice weekly) or subcutaneous erythropoietin alfa (50 IU/kg two to three times weekly). Doses were adjusted to maintain haemoglobin (Hb) between 10-11 g/dl. Hematological and biochemical parameters were assessed at baseline, one month and three months.
Results: A total of 109 patients were randomized: 54 to desidustat and 55 to erythropoietin. Baseline characteristics, including age, weight and BMI, were comparable. Both groups showed a significant increase in haemoglobin from baseline to follow-ups (p<0.001). At three months, mean Hb rose by 1.65 g/dl in the desidustat group and by 1.31 g/dl in the erythropoietin group.
Conclusions: Desidustat demonstrated efficacy and safety comparable to erythropoietin in managing CKD-associated anemia. Its oral administration offers practical advantages, supporting its role as a promising alternative pending further large-scale studies.
Metrics
References
Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher haemoglobin concentration does not increase mortality among hemodialysis patients. J American Soc Nephrol. 2011;22(2):358-65. DOI: https://doi.org/10.1681/ASN.2010020173
Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. American J Kidney Dis. 2018;71(3):423-35. DOI: https://doi.org/10.1053/j.ajkd.2017.09.026
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PloS one. 2014;9(1):84943. DOI: https://doi.org/10.1371/journal.pone.0084943
Stierman B, Afful J, Carroll MD, Chen TC, Davy O, Fink S, et al. National health and nutrition Examination Survey 2017-March 2020 prepandemic data files-development of files and prevalence estimates for selected health outcomes. National health statistics reports. 2021;14(158):10-5620.
Анемії К. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2:279.
Carmeleit P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1 in hypoxia mediated apoptosis, cell proliferation and angiogenesis. Nature. 1998;394:485-90. DOI: https://doi.org/10.1038/28867
Vogel S, Wottawa M, Farhat K, Zieseniss A, Schnelle M, Le-Huu S, von Ahlen M, Malz C, Camenisch G, Katschinski DM. Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem. 2010;285(44):33756-63. DOI: https://doi.org/10.1074/jbc.M110.132985
Eckardt KU. The noblesse of kidney physiology. Kidney Int. 2019;96(6):1250-3. DOI: https://doi.org/10.1016/j.kint.2019.10.007
Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. American J Physiol Renal Physiol. 2010;298(6): F1287-96. DOI: https://doi.org/10.1152/ajprenal.00736.2009
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New England J Med. 1987;316(2):73-8. DOI: https://doi.org/10.1056/NEJM198701083160203
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. New England J Med. 2006;355(20):2085-98. DOI: https://doi.org/10.1056/NEJMoa065485
Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl.2021;11(1):8-25. DOI: https://doi.org/10.1016/j.kisu.2020.12.002
Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RJ, Shah CY. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability and pharmacokinetics following oral administration in healthy volunteers. Clinical Pharmacokinetics. 2018;57:87-102. DOI: https://doi.org/10.1007/s40262-017-0551-3
Jin C, Zhang Y, Luo C, Ren Y, Ye B, Hu X, Li Y, Zhu B, He Q, Shao L. Comparison of efficacy of roxadustat and erythropoietin for the treatment of renal anemia in patients with chronic kidney disease: a retrospective study. Translational Androl Urol. 2022;11(11):1568. DOI: https://doi.org/10.21037/tau-22-709
Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U, et al. Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D). American J Nephrol. 2022;53(5):343-51. DOI: https://doi.org/10.1159/000523949
Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, et al. Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). American J Nephrol. 2022;53(5):352-60. DOI: https://doi.org/10.1159/000523961
Joharapurkar AA, Patel VJ, Kshirsagar SG. Hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Curr Res Pharmacol Drug Dis. 2022;3:100102. DOI: https://doi.org/10.1016/j.crphar.2022.100102
Zheng Q, Yang H, Sun L, Wei R, Fu X. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis. Pharmacol Res. 2020;159:105020. DOI: https://doi.org/10.1016/j.phrs.2020.105020
Downloads
Published
How to Cite
Issue
Section
